Ozempic Blood Cancer Risk Study: Canadian Researchers Investigate GLP-1 Drugs' Protective Effects

Canadian Researchers Launch Landmark Study on Ozempic and Blood Cancer Prevention

Exciting developments are emerging from Canada's leading cancer research institutions as scientists delve into the potential protective effects of GLP-1 drugs like Ozempic against blood cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), the class of medications including semaglutide marketed as Ozempic, have revolutionized diabetes management and weight loss. Now, a newly funded five-year study at Toronto's Princess Margaret Cancer Centre is investigating whether these drugs could also lower the risk of acute myeloid leukemia (AML), a aggressive form of blood cancer.

Led by senior scientist Dr. Steven Chan in collaboration with Dr. Stephanie Xie and pioneering endocrinologist Dr. Daniel Drucker, this research addresses a critical gap. With obesity and type 2 diabetes rates climbing in Canada—over 3 million Canadians living with diabetes and up to 1.4 million using GLP-1 drugs—these common conditions heighten cancer risks through chronic inflammation. The study, backed by $2 million from a $41 million national investment in cancer prevention, could redefine preventive strategies for age-related blood disorders.

This initiative highlights Canada's commitment to translational research, bridging lab discoveries to clinical impact at university-affiliated centers like Princess Margaret, part of the University Health Network (UHN) and University of Toronto.

Understanding GLP-1 Drugs: From Diabetes Treatment to Potential Cancer Shield

GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, naturally released in the gut after eating. This hormone stimulates insulin release, slows gastric emptying, and signals fullness to the brain, aiding blood sugar control and appetite suppression. Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide, a dual GLP-1/GIP agonist) exemplify this class, with weekly injections transforming obesity care.

In Canada, GLP-1 prescriptions surged amid the obesity epidemic, where 27% of adults are obese. These drugs achieve 15-20% weight loss, far surpassing lifestyle interventions. Beyond metabolic benefits, preclinical data reveal anti-inflammatory properties: GLP-1RAs reduce pro-inflammatory cytokines, modulate immune cells, and stabilize vascular endothelium—key in preventing chronic diseases.

Dr. Daniel Drucker, whose decades of work at the Lunenfeld-Tanenbaum Research Institute uncovered GLP-1's therapeutic potential, co-leads this effort. His foundational studies paved the way for these drugs, earning international accolades like the 2025 Breakthrough Prize.

The Burden of Blood Cancers in Canada: Focus on Acute Myeloid Leukemia

Blood cancers, or hematologic malignancies, encompass leukemias, lymphomas, and myelomas. AML stands out for its rapid progression, primarily affecting older adults. In Canada, approximately 1,165 new AML cases are diagnosed annually, with 635 in men and 530 in women. The five-year survival rate hovers at 26%, underscoring the need for prevention.

• AML arises from uncontrolled proliferation of immature myeloid cells in bone marrow, disrupting normal blood production.
• Risk factors include age (median diagnosis 68 years), prior chemotherapy, radiation, and genetic predispositions like clonal hematopoiesis.
• Obesity and diabetes exacerbate risks via insulin resistance and inflammation.

Clonal hematopoiesis of indeterminate potential (CHIP) or CH, detected in 10% of people over 70, involves somatic mutations in hematopoietic stem cells (HSCs). While often benign, CHIP elevates AML risk 5-10 fold and cardiovascular disease. Canadian researchers aim to intervene early.

Clonal Hematopoiesis: The Precursor Puzzle GLP-1 Drugs May Solve

Step-by-step, clonal hematopoiesis unfolds: Aging HSCs accumulate mutations (e.g., in DNMT3A, TET2, ASXL1 genes). Mutant clones expand under inflammatory stress, gaining survival advantages. Chronic inflammation from obesity fuels this via cytokines like IL-6 and TNF-alpha, promoting mutant HSC dominance.

Dr. Steven Chan, MD/PhD from Stanford and Senior Scientist at PM since 2015, specializes in targeting these mutations. His prior work showed metformin curbs mutant HSC growth. Now, GLP-1RAs' anti-inflammatory effects—reducing NF-kB signaling and macrophage activation—could similarly suppress clones.

Dr. Stephanie Xie, Scientist at PM, complements this by studying how inflammation and metabolic stress perturb HSCs and leukemia stem cells. Her lab's insights into stress responses will guide mechanistic probes.

Study Design: Rigorous Science to Uncover Protective Mechanisms

Over five years, the team will employ multi-omics: single-cell RNA sequencing of patient-derived HSCs, CRISPR-edited models to test GLP-1RA impacts on mutant clones, and prospective cohorts tracking CHIP patients on/off GLP-1 therapy. Endpoints include clone size reduction, AML progression rates, and inflammation biomarkers.

This builds on global evidence where GLP-1 users showed 54% lower hematologic malignancy risk versus insulin, including AML precursors like MDS and MPNs. Funded by CIHR, Terry Fox Research Institute (TFRI site), and partners, it's among three GLP-1 cancer prevention projects.

Photo by Markus Winkler on Unsplash

Preliminary Evidence: GLP-1's Broad Anti-Cancer Signals

Beyond blood cancers, U.S. studies report GLP-1 users have 7-17% lower obesity-related cancer incidence (colorectal, endometrial) and halved colon cancer mortality. Mechanisms: direct tumor suppression, immune modulation, gut microbiome shifts.

A Cleveland Clinic analysis linked GLP-1 to fewer MPNs/MDS in diabetics, attributing to inflammation control. Canadian data aligns, with obesity driving 4-8% of cancers here.

For aspiring researchers, opportunities abound in higher ed research jobs at institutions like U of T.

Implications for Canadian Healthcare and Patients

Success could repurpose GLP-1s for high-risk CHIP patients (e.g., elderly diabetics), averting AML's $100K+ treatment costs per case. Amid Canada's aging population (20% over 65 by 2030), prevention eases system strain.

Dr. Fei-Fei Liu, CIHR's Institute director, notes GLP-1s "revolutionized disease thinking," with signals of cancer risk reduction. Dr. Chan emphasizes preventing suffering and burden reduction.

Patients should consult physicians; ongoing trials monitor long-term safety.

Spotlight on Princess Margaret: A Hub for Innovative Cancer Research

Affiliated with U Toronto, PM ranks among world's top cancer centers, pioneering immunotherapies and precision medicine. Chan's lab develops real-time genetic tracking tools; Xie's explores leukemia stem cell vulnerabilities.

Such hubs foster careers; explore postdoc success tips or Canadian academic jobs.

Global Context and Future Directions

While U.S./European trials focus solid tumors, Canada's blood cancer angle is unique. If validated, Phase II trials could follow by 2030. Challenges: long latency, confounders like weight loss.

Optimism prevails; GLP-1s may join statins/aspirin as preventives. For students, research assistant roles offer entry.

Careers in Cancer Prevention Research: Opportunities in Canada

This study exemplifies demand for experts in hematology, endocrinology, bioinformatics. UHN/PM recruits postdocs, faculty amid expansion. Salaries average $120K+ for PhDs; check university jobs, higher ed jobs.

Actionable advice: Build wet-lab skills, collaborate interdisciplinary. Resources like academic CV tips aid transitions.

Photo by Artyom Korshunov on Unsplash

• Pursue MSc/PhD in medical biophysics at U Toronto.
• Network via Terry Fox programs.
• Target grants from CIHR.

Conclusion: A Promising Frontier in Preventive Oncology

The Ozempic blood cancer risk study heralds hope, potentially harnessing GLP-1 drugs' anti-inflammatory power against AML precursors. Canadian leadership at PM positions us globally. Stay informed via Rate My Professor for mentors, higher-ed-jobs for roles, career advice. Engage in comments below.